



165 – 10551 Shellbridge Way, Richmond, BC, V6X 2W8

BioMark’s Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing

The Company will leverage Raman spectroscopy and Machine Learning as part of its diagnostics

Vancouver, British Columbia – (July 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that its affiliated company, Bio-Stream Diagnostics Inc., will be working with University of Qatar’s Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine vibrational modes of molecules, although rotational and other low-frequency modes of systems may also be observed. Raman spectroscopy is commonly used in chemistry to provide a structural fingerprint by which molecules can be identified.

Professor Al- Maadeed heads the Computer Science and Engineering Department at Qatar University with research interests in Pattern Recognition, Image and Signal Processing, AI, Bio-Metrics, Character Recognition, Writer Identification, and Digital Library. Prof Al-Maadeed is a recent recipient of a grant from Qatar University’s Predicting Risk Early in COVID-19 -The PERIL Study which fits very well with Bio- Stream’s research and future commercialization objectives.

“We are delighted to have Professor Al- Maadeed and her dedicated group from Qatar University to be part of our research team with a special focus on the use of ML in rapid COVID -19 diagnosis,” said Mr. Rashid A. Bux, President & CEO of BioMark Diagnostics, Inc. “The additional ML resources and talent that both Professor Al-Maadeed and Qatar University provide will complement our already strong ML group. This collaboration demonstrates our global intent to partner with leading institutions and organizations that are seeking ways to bringing in rapid, effective and economical COVID -19 screening solutions to market.”

About Qatar University

Since its inception in 1977, Qatar University (QU) continues to serve as Qatar’s primary institution of higher education and has become today a beacon of academic and research excellence in the region. QU hosts ten colleges -- College of Arts and Sciences (CAS), College of Business and Economics (CBE), College of Education (CED), College of Engineering (CENG), College of Health Sciences (CHS), College of Law (LAWC), College of Medicine (CMED), College of Pharmacy (CPH), College of Sharia and Islamic Studies (CSIS) and College of Dental Medicine (CDM). Research is an integral part of the academic environment at QU and is bolstered by the state-of-the-art Research Complex, and 14 research centers of excellence. It is further enhanced by over 400 collaborative projects in over 130 countries.

Community engagement is an area stationed at the heart of QU's mission and vision. The University prides itself on the quality of its students and alumni and is committed to ensuring that campus life is an enriching environment for encouraging academic excellence, volunteerism, civic responsibility, and leadership. QU is advancing its goal to become a leader of economic and social development in Qatar through collaborations and partnerships with industry, government, academia, business, and civil society in Qatar and beyond.

About Bio Stream Diagnostics Inc.

Bio Stream Diagnostics Inc. intends to develop a novel COVID-19-detection method leveraging new generation Raman spectroscopy and the power of machine learning an alternative detection tool to polymerase chain reaction (PCR) detection arrays and other detection systems.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.